Drug-induced end-stage renal disease (ESRD) is a significant and preventable health crisis, resulting from the toxic effects of medications on the kidneys. Despite advances in pharmacology and therapeutic interventions, many individuals develop renal failure due to long-term exposure to nephrotoxic drugs. This paper explores the various approaches for preventing and managing drug-induced ESRD, focusing on early detection, therapeutic strategies, and best practices for treatment. Prevention is paramount and involves careful selection of drugs, dosing adjustments, and close monitoring of renal function. Management strategies for patients diagnosed with drug-induced kidney damage include discontinuation of the offending drugs, the use of nephroprotective agents, and appropriate dialysis or kidney transplantation when necessary. Additionally, the paper discusses the role of healthcare professionals in educating patients and minimizing the risks associated with nephrotoxic medications. By adopting a multidisciplinary approach and promoting better monitoring systems, healthcare providers can reduce the incidence of drug-induced ESRD and improve patient outcomes. This paper emphasizes the importance of preventive care, early intervention, and the adoption of evidence-based treatment solutions to tackle this growing public health issue.

Drug-induced ESRD, nephrotoxicity, renal failure

Kellum JA, Levin N, Bouman C, Lameire N. Curr Opin Crit Care, 2002;8:509-514.

Mehta RL, Chertow GM. J Am Soc Nephrol, 2003; 14:2178-2187.

Whelton A. Am J Med, 1999; 106:13S-24S.

Han WK, Bailly V, Abichandani R. Kidney Int, 2002; 62:237-244.

Baliga R, Ueda N, Walker PD, Shah SV. Drug Metab Rev, 1999; 31:971-997.

Swan SK. Semin Nephrol, 1997; 17:27-33.

Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Semin Nephrol, 1997; 17:15-26.

Solomon R.. Kidney Int, 1998;53:230-242.

Murphy SW, Barrett BJ, Parfrey PS. J Am Soc Nephrol, 2000; 11:177-182.

Waybill MM, Waybill PN. JV asc Intervent Radiol, 2001; 12:3- 9.